KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Equity Ratio: 2010-2024

Historic Equity Ratio for TherapeuticsMD (TXMD) over the last 15 years, with Dec 2024 value amounting to 0.71.

  • TherapeuticsMD's Equity Ratio rose 3.60% to 0.71 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.71, marking a year-over-year increase of 3.60%. This contributed to the annual value of 0.71 for FY2024, which is 4.26% up from last year.
  • Per TherapeuticsMD's latest filing, its Equity Ratio stood at 0.71 for FY2024, which was up 4.26% from 0.68 recorded in FY2023.
  • Over the past 5 years, TherapeuticsMD's Equity Ratio peaked at 0.71 during FY2024, and registered a low of -0.68 during FY2020.
  • Moreover, its 3-year median value for Equity Ratio was 0.68 (2023), whereas its average is 0.59.
  • Its Equity Ratio has fluctuated over the past 5 years, first plummeted by 2,073.82% in 2020, then spiked by 170.33% in 2022.
  • TherapeuticsMD's Equity Ratio (Yearly) stood at -0.68 in 2020, then climbed by 19.09% to -0.55 in 2021, then spiked by 170.33% to 0.39 in 2022, then surged by 74.06% to 0.68 in 2023, then increased by 4.26% to 0.71 in 2024.